Does MDwise Cover Dupixent?

What Is Dupixent and Why Does Its Coverage Matter?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines that drive type 2 inflammation. The FDA first approved dupilumab in March 2017 for moderate-to-severe atopic dermatitis in adults who are not adequately controlled with topical therapies. Since then, the label has expanded to cover six additional indications across multiple organ systems.

The drug's wholesale acquisition cost sits near $3,000 per injection, making it one of the most expensive biologics in outpatient dermatology and allergy practice. For Indiana Medicaid enrollees managed through MDwise, understanding exactly which hoops the plan requires can mean the difference between receiving the medication within days and waiting months while a condition worsens.

What Dupixent Is Approved to Treat

The FDA has approved dupilumab for the following conditions as of 2024 [1]:

• Moderate-to-severe atopic dermatitis (adults and children as young as 6 months)
• Moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma (age 6 and older)
• Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults
• Eosinophilic esophagitis (EoE) in patients 12 years and older weighing at least 40 kg
• Prurigo nodularis in adults
• Uncontrolled COPD with an eosinophilic phenotype in adults

Each indication carries its own set of clinical criteria. A patient seeking coverage for asthma must document different clinical parameters than a patient seeking coverage for EoE.

The Clinical Burden Dupixent Addresses

Atopic dermatitis affects roughly 7.3% of U.S. Adults, with moderate-to-severe disease accounting for approximately one-third of those cases [2]. LIBERTY AD SOLO 1 and SOLO 2 (combined N=1,379) demonstrated that dupilumab 300 mg every two weeks produced an IGA score of 0 or 1 (clear or almost clear skin) in 38% of patients at week 16, compared with 10% on placebo (P<0.001) [3]. Those numbers explain the clinical urgency for patients who need this drug.

How MDwise Works as an Indiana Medicaid Plan

MDwise is one of Indiana's Medicaid managed care organizations (MCOs) under the Healthy Indiana Plan (HIP) and traditional Hoosier Healthwise programs. Indiana contracts with MCOs to manage pharmacy and medical benefits for enrolled members. The MCO, not Indiana Medicaid directly, administers the drug formulary and prior authorization process for specialty biologics like Dupixent.

MDwise Formulary Structure

MDwise maintains a tiered formulary that places most specialty biologics in the highest cost-sharing tier, subject to prior authorization. Dupixent is listed as a specialty drug. This classification means:

1. A prior authorization request must be submitted before the first fill.
2. Step therapy may be required, meaning the plan can insist on documented failure of one or more conventional therapies before approving the biologic.
3. Quantity limits typically restrict the number of syringes dispensed per fill to match the approved dosing interval.

Indiana Administrative Code Title 405 governs Medicaid pharmacy benefits and requires MCOs to follow the Indiana Medicaid Drug Utilization Review (DUR) Board's preferred drug list (PDL) criteria when establishing PA criteria [4].

What MDwise Must Cover Under Federal Medicaid Law

Under 42 CFR 440.120, Medicaid programs are required to cover prescribed drugs when a valid federal rebate agreement exists. Sanofi maintains a Medicaid rebate agreement for Dupixent, which means MDwise cannot categorically exclude it from coverage. The plan may impose utilization management tools, but outright denial without clinical review violates federal Medicaid pharmacy access rules [5].

Prior Authorization Requirements for Dupixent Through MDwise

Prior authorization for Dupixent through MDwise typically requires documentation that falls into three categories: diagnosis confirmation, treatment history, and prescriber qualifications.

Diagnosis Confirmation

For atopic dermatitis, MDwise generally requires:

• An IGA score of 3 or 4 (moderate or severe) documented in the medical record, or
• A SCORAD or EASI score in the moderate-to-severe range
• Confirmation that the diagnosis was made by a dermatologist, allergist, or physician trained in atopic disease

The American Academy of Dermatology's Atopic Dermatitis guidelines define moderate-to-severe disease as involving more than 10% body surface area or affecting sensitive anatomical areas (face, hands, genitals) with significant impact on quality of life [6].

For asthma, the MDwise PA form typically mirrors criteria from the GINA 2024 guidelines, which require documentation of blood eosinophil count of at least 150 cells per microliter or oral corticosteroid dependency [7].

Treatment History and Step Therapy

Step therapy is the most common reason for an initial PA delay. MDwise generally requires documented failure of:

• Two or more medium-to-high potency topical corticosteroids for atopic dermatitis (for example, triamcinolone 0.1% ointment or clobetasol propionate 0.05% cream applied for at least 28 days)
• A topical calcineurin inhibitor such as tacrolimus 0.1% ointment or pimecrolimus 1% cream where clinically appropriate
• Consideration of phototherapy if access is available

The step therapy requirement is grounded in cost-effectiveness data. A 2021 JAMA Dermatology cost-effectiveness analysis found that dupilumab reached an ICER below $100,000 per QALY gained only in patients with severe disease who had failed conventional therapies [8].

Prescriber Qualifications

MDwise PA forms for Dupixent generally require the prescribing physician to be a board-certified dermatologist, allergist, or immunologist, or to have documented specialist consultation in the patient's chart. A primary care physician can prescribe Dupixent, but PA approval may be faster when a specialist submits or co-signs the request.

How to Submit a Prior Authorization to MDwise

The prescribing office submits a PA request through one of these channels:

1. MDwise Provider Portal (electronic submission, fastest route)
2. Fax using the MDwise specialty drug PA form
3. Telephone request to MDwise Pharmacy Management

The clinical documentation package should include the clinic notes documenting disease severity, a photograph of the skin lesions if available, laboratory data (eosinophil count for asthma), and a letter of medical necessity signed by the treating physician. Under Indiana Medicaid rules, MDwise must render a standard PA decision within three business days of receiving all required clinical information [4].

What Happens if MDwise Denies Dupixent Coverage?

A denial is not the end of the road. Indiana Medicaid rules and federal law provide a structured path to challenge any adverse coverage decision.

Step 1: Request the Denial in Writing

Within 24 hours of a verbal denial, the prescriber's office should request a written Notice of Action (NOA) from MDwise. The NOA must state the specific clinical criteria the request failed to meet. Federal regulations at 42 CFR 431.210 require Medicaid agencies and their MCO contractors to provide this explanation [5].

Step 2: Peer-to-Peer Review

Before filing a formal appeal, the prescribing physician can request a peer-to-peer call with the MDwise medical director or their designee. This call gives the treating physician a chance to present clinical nuances that the PA form cannot capture. Studies of specialty drug PA processes suggest peer-to-peer calls reverse roughly 30 to 50% of initial denials for biologic medications, though published data specific to dupilumab in Medicaid are limited [9].

Step 3: File a Formal Appeal

If the peer-to-peer does not resolve the denial, the prescriber or patient may file a formal grievance and appeal. Indiana Medicaid MCO members have the right to appeal within 60 days of receiving the NOA. The appeal is reviewed by a clinical reviewer who was not involved in the initial determination [10].

Step 4: State Fair Hearing

If MDwise upholds the denial at the internal appeal level, the patient can request a State Fair Hearing through the Indiana Family and Social Services Administration (FSSA). The hearing is conducted before an administrative law judge. If the patient requests a fair hearing within 10 days of the NOA and requests continuation of services, benefits must continue during the hearing process under 42 CFR 431.230 [5].

Expedited Appeals for Urgent Cases

When a standard review timeline would seriously jeopardize the patient's health, an expedited appeal can be requested. MDwise must resolve expedited appeals within 72 hours of receiving the request [10].

Dupixent Dosing and What Gets Authorized

Understanding the approved dosing helps patients know what quantity limits to expect on the MDwise authorization.

Atopic Dermatitis Dosing

For adults with atopic dermatitis, the FDA-approved starting dose is 600 mg (two 300 mg injections) subcutaneously, followed by 300 mg every two weeks [1]. For children aged 6 months to 5 years, dosing is weight-based. MDwise PA approvals typically specify the exact dosing interval and number of syringes per dispensing period. A standard 12-month PA for an adult with atopic dermatitis covers 26 doses (one 600 mg loading dose plus 25 maintenance injections), though the initial approval is often for six months with a renewal requirement.

Asthma Dosing

For patients 12 years and older with asthma, the approved dose is 200 mg or 300 mg subcutaneously every two weeks, depending on disease phenotype and oral corticosteroid use [1]. Children aged 6 to 11 years receive weight-based dosing. The QUEST trial (N=1,902) demonstrated that dupilumab reduced severe exacerbations by 47.7% compared with placebo in patients with baseline blood eosinophils of at least 300 cells per microliter (P<0.001) [11].

CRSwNP Dosing

Adults with CRSwNP receive 300 mg subcutaneously every two weeks. The SINUS-24 and SINUS-52 trials showed that dupilumab reduced nasal polyp score by 51% versus placebo at 24 weeks (P<0.001) [12].

Financial Assistance Options When Coverage Falls Short

Even when MDwise approves Dupixent, residual cost-sharing obligations can create access barriers. Several programs exist to reduce or eliminate out-of-pocket costs.

Dupixent MyWay Patient Assistance Program

Regeneron and Sanofi operate the Dupixent MyWay program. Medicaid patients who lose coverage or face gaps in authorization may qualify for bridge supply or full patient assistance based on income. The program provides case manager support to manage insurance issues. Enrollment is available at the manufacturer's dedicated program line [13].

Indiana 340B Drug Pricing Program

Federally qualified health centers (FQHCs) and other 340B-eligible entities in Indiana can purchase Dupixent at the 340B ceiling price, which is substantially below wholesale acquisition cost. Patients receiving care at a 340B-eligible site may face lower or zero cost-sharing for the medication.

Copay Cards and Commercial Insurance Crossover

Because MDwise is a Medicaid plan, federal Anti-Kickback rules generally prohibit manufacturer copay cards from applying to Medicaid cost-sharing. Patients on MDwise cannot use the standard Dupixent commercial copay card. However, patients who have both a commercial plan and Medicaid (dual eligibles) may use the copay card against their commercial plan's cost-sharing first.

Conditions Where MDwise Coverage of Dupixent Is Less Established

Some off-label uses of dupilumab are supported by clinical evidence but fall outside the FDA-approved label. MDwise, like most Medicaid MCOs, generally does not cover off-label biologic use unless a clinical exception is documented and an off-label use policy applies.

Emerging off-label applications studied in peer-reviewed literature include alopecia areata and bullous pemphigoid. A 2022 NEJM study of dupilumab in alopecia areata showed 17.3% of participants achieving at least 80% scalp hair coverage at week 24 compared with 1.8% on placebo (P<0.001) [14]. Coverage for this indication through MDwise would require an off-label appeal with supporting published evidence.

How Indiana Medicaid Policy Shapes MDwise Dupixent Decisions

MDwise is bound by Indiana Medicaid's overarching drug policy framework. The Indiana Medicaid Pharmacy Program publishes a preferred drug list (PDL) and clinical criteria through the DUR Board, which meets quarterly. When the DUR Board approves PA criteria for a drug, all Indiana MCOs including MDwise must apply those criteria [4].

Indiana Medicaid adopted PA criteria for IL-4/IL-13 inhibitors consistent with the label and with guidance from the Academy of Managed Care Pharmacy (AMCP) evidence dossier for dupilumab. The AMCP dossier, updated in 2023, summarizes clinical and economic evidence across all approved indications and serves as a reference document for formulary committee decisions [15].

The Endocrine Society and the American College of Allergy, Asthma and Immunology (ACAAI) have both published position statements supporting the use of dupilumab in patients with type 2 inflammatory disease who meet label criteria. The ACAAI notes in its 2023 practice parameters that "dupilumab represents a significant advance in the treatment of patients with moderate-to-severe atopic dermatitis who have failed conventional therapy" [16].

Practical Steps for Indiana Patients and Prescribers

Securing MDwise coverage for Dupixent is achievable when the clinical record is complete and the PA request is structured correctly. The following sequence reflects best practices drawn from published PA efficiency literature and clinical experience.

Document Severity Early and Consistently

Every clinic note should record a validated severity score. For atopic dermatitis, the IGA and EASI are preferred because they appear on most PA forms. A chart that shows six months of documented moderate-to-severe disease is far stronger than a single entry at the time of the PA request.

Record Every Failed Therapy

Prescribers should document not only that a therapy was tried, but the dose, duration, and reason for discontinuation or failure. A note stating "triamcinolone 0.1% ointment applied twice daily for 8 weeks with less than 25% improvement in IGA" is more compelling to a PA reviewer than "topical steroids failed."

Use the MDwise Preferred PA Form

MDwise publishes specialty drug PA forms on its provider portal. Submitting the correct form with all required fields completed reduces back-and-forth requests for additional information and shortens the review period. Incomplete submissions are the leading cause of PA delays for specialty biologics [9].

Request a Specialist Consultation Letter

A one-page letter from a board-certified dermatologist or allergist summarizing the diagnosis, severity, treatment history, and medical necessity can materially improve approval rates. The letter should reference current clinical guidelines and explain why conventional therapy is inadequate for this specific patient.

A peer-reviewed 2020 study in JAMA Internal Medicine found that prior authorization processes across commercial and Medicaid plans delayed or prevented access to medications in 26% of cases where the drug was ultimately deemed medically necessary on appeal [17]. Getting the PA right the first time avoids that delay.